SEARCH:   Advanced

Blood, 15 September 2008, Vol. 112, No. 6, pp. 2205-2213. Prepublished online as a Blood First Edition Paper on June 30, 2008; DOI 10.1182/blood-2008-02-140673. This Article Full Text Full Text (PDF) All Versions of this Article: blood-2008-02-140673v1 112/6/2205    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Chiron, D. Articles by Jego, G. Search for Related Content PubMed PubMed Citation Articles by Chiron, D. Articles by Jego, G. Related Collections Immunobiology Neoplasia Review Articles Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  REVIEW ARTICLE Toll-like receptors: lessons to learn from normal and malignant human B cells David Chiron1, Isabelle Bekeredjian-Ding2, Catherine Pellat-Deceunynck1, Régis Bataille1, and Gaëtan Jego1 1 Inserm U892, Nantes, France; and 2 Department of Medical Microbiology and Hygiene, University Hospital Heidelberg, Heidelberg, Germany The humoral immune system senses microbes via recognition of specific microbial molecular motifs by Toll-like receptors (TLRs). These encounters promote plasma cell differentiation and antibody production. Recent studies have demonstrated the importance of the TLR system in enhancing antibody-mediated defense against infections and maintaining memory B cells. These results have led the way to the design of vaccines that target B cells by engaging TLRs. In hematologic malignancies, cells often retain B cell–specific receptors and associated functions. Among these, TLRs are currently exploited to target different subclasses of B-cell leukemia, and TLR agonists are currently being evaluated in clinical trials. However, accumulating evidence suggests that endogenous TLR ligands or chronic infections promote tumor growth, thus providing a need for further investigations to decipher the exact function of TLRs in the B-cell lineage and in neoplastic B cells. The aim of this review is to present and discuss the latest advances with regard to the expression and function of TLRs in both healthy and malignant B cells. Special attention will be focused on the growth-promoting effects of TLR ligands on leukemic B cells and their potential clinical impact. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: D. Chiron, C. Pellat-Deceunynck, M. Amiot, R. Bataille, and G. Jego TLR3 Ligand Induces NF-{kappa}B Activation and Various Fates of Multiple Myeloma Cells Depending on IFN-{alpha} Production J. Immunol., April 1, 2009; 182(7): 4471 - 4478. [Abstract] [Full Text] [PDF] P. D. Crompton, M. Mircetic, G. Weiss, A. Baughman, C.-Y. Huang, D. J. Topham, J. J. Treanor, I. Sanz, F. E.-H. Lee, A. P. Durbin, et al. The TLR9 Ligand CpG Promotes the Acquisition of Plasmodium falciparum-Specific Memory B Cells in Malaria-Naive Individuals J. Immunol., March 1, 2009; 182(5): 3318 - 3326. [Abstract] [Full Text] [PDF]

	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020